 |
The Journal of Neuroscience, February 11, 2004, 24(6):1451-1458; doi:10.1523/JNEUROSCI.1517-03.2004
Previous Article | Next Article 
Behavioral/Systems/Cognitive
Nonopioid Actions of Intrathecal Dynorphin Evoke Spinal Excitatory Amino Acid and Prostaglandin E2 Release Mediated by Cyclooxygenase-1 and -2
Lee Koetzner,1
Xiao-Ying Hua,1
Josephine Lai,3
Frank Porreca,3,4 and
Tony Yaksh1,2
Departments of 1Anesthesiology and 2Pharmacology, University of California, San Diego, La Jolla, California 92093, and Departments of 3Pharmacology and 4Anesthesiology, University of Arizona, Tucson, Arizona 85724
Spinal dynorphin is hypothesized to contribute to the hyperalgesia that follows tissue and nerve injury or sustained morphine exposure. We considered that these dynorphin actions are mediated by a cascade involving the spinal release of excitatory amino acids and prostaglandins. Unanesthetized rats with lumbar intrathecal injection and loop dialysis probes received intrathecal NMDA, dynorphin A(1-17), or dynorphin A(2-17). These agents elicited an acute release of glutamate, aspartate, and taurine but not serine. The dynorphin peptides and NMDA also elicited a long-lasting spinal release of prostaglandin E2. Prostaglandin release evoked by dynorphin A(2-17) or NMDA was blocked by the NMDA antagonist amino-5-phosphonovalerate as well the cyclooxygenase (COX) inhibitor ibuprofen. To identify the COX isozyme contributing to this release, SC 58236, a COX-2 inhibitor, was given and found to reduce prostaglandin E2 release evoked by either agent. Unexpectedly, the COX-1 inhibitor SC 58560 also reduced dynorphin A(2-17)-induced, but not NMDA-induced, release of prostaglandin E2. These findings reveal a novel mechanism by which elevated levels of spinal dynorphin seen in pathological conditions may produce hyperalgesia through the release of excitatory amino acids and in part by the activation of a constitutive spinal COX-1 and -2 cascade.
Key words: dynorphin; NMDA; aspartate; glutamate; prostaglandin E2; cyclooxygenase
Received May 21, 2003;
revised October 6, 2003;
accepted December 5, 2003.
This article has been cited by other articles:

|
 |

|
 |
 
T. J. Martin, N. L. Buechler, and J. C. Eisenach
Intrathecal administration of a cylcooxygenase-1, but not a cyclooxygenase-2 inhibitor, reverses the effects of laparotomy on exploratory activity in rats.
Anesth. Analg.,
September 1, 2006;
103(3):
690 - 695.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Hiller, O. A. Meretoja, R. Korpela, S. Piiparinen, and T. Taivainen
The analgesic efficacy of acetaminophen, ketoprofen, or their combination for pediatric surgical patients having soft tissue or orthopedic procedures.
Anesth. Analg.,
May 1, 2006;
102(5):
1365 - 1371.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Koetzner, J. A. Gregory, and T. L. Yaksh
Intrathecal Protease-Activated Receptor Stimulation Produces Thermal Hyperalgesia through Spinal Cyclooxygenase Activity
J. Pharmacol. Exp. Ther.,
October 1, 2004;
311(1):
356 - 363.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|